B of A Securities Maintains Buy on Relay Therapeutics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Relay Therapeutics and raises the price target from $20 to $24.
September 10, 2024 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on Relay Therapeutics and increased the price target from $20 to $24, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and an increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100